New PD-1 Immunotherapy Combinations Push The Envelope In Melanoma
Early data from small studies presented at the Society of Melanoma Research meeting suggest potential for safely and effectively combining PD-1 inhibitors with a range of drugs, including Amgen’s Imlygic vaccine.
You may also be interested in...
Bristol's Opdivo and Novartis/GlaxoSmithKline's Tafinlar/Mekinist combo both performed well in early, post-surgical treatment of advanced melanoma in trials reported at ESMO, promising yet another revolution in the standard of care, but leaving Roche's Zelboraf/Cotellic in the dust.
Company plans to pursue accelerated approval based on a single-arm registrational study of PD-1 failures, after reporting positive results from a Phase II study at the ASCO-SITC meeting.
First adjuvant and combination approvals for immuno-oncology could help revive Yervoy in melanoma; Amgen’s oncolytic cancer vaccine emerges as new mechanism for select patients, with room to grow.